Assembly Biosciences (ASMB) News Today

Assembly Biosciences, Inc. (NASDAQ: ASMB) shares have increased as investors respond to improving earnings expectations, favorable analyst sentiment and strong momentum rankings. The company’s recent quarterly results also provide support: it beat EPS and revenue expectations, reporting a loss of $0.20 per share versus the $0.72 consensus loss and revenue of $13.37 million versus $8.60 million expected.

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $2.28 from $1.90 and maintained a “Buy” rating with a $50 price target, signaling improved expectations for the company’s near-term earnings. HC Wainwright Assembly Biosciences estimates
• Positive Sentiment: The analyst also raised estimates for several periods, including Q3 2026 EPS to a loss of $0.44 from a loss of $0.69, Q1 2027 EPS to positive $0.02 from a loss of $0.16, and FY2027 EPS to a loss of $0.02 from a loss of $0.77. These revisions suggest expectations for a substantially better earnings trajectory.
• Positive Sentiment: Assembly Biosciences was added to Zacks’ Rank #1 (Strong Buy) list and its momentum-focused Strong Buy list. Such rankings may attract momentum-oriented investors, although they are based largely on quantitative factors. Zacks momentum stocks
• Positive Sentiment: Analysts continue to show constructive sentiment: HC Wainwright reiterated its “Buy” rating, while the broader analyst consensus was reported as “Moderate Buy.” Another Zacks analysis cited average analyst price targets implying significant potential upside, while cautioning that price targets are an imperfect forecasting tool. HC Wainwright Buy rating
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to $3.19 from $3.69, partially offsetting the broader upward revisions. The company remains dependent on future earnings improvements, and analyst forecasts for some 2027 quarters still call for losses.